Sopharma AD (BUL: SFA)

Market Cap	954.68M
Revenue (ttm)	2.05B
Net Income (ttm)	81.91M
Shares Out	165.74M
EPS (ttm)	0.46
PE Ratio	12.45
Forward PE	n/a
Dividend	0.15 (2.60%)
Ex-Dividend Date	Nov 7, 2024

Volume	140
Average Volume	9,146
Open	5.72
Previous Close	5.76
Day's Range	5.72 - 5.76
52-Week Range	5.56 - 6.68
Beta	-0.03
RSI	52.43
Earnings Date	Jan 30, 2025

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. The company operates through Production of Pharmaceutical Products; Distribution of Pharmaceutical Products (Goods); and Others. It offers Carsil to treat liver disease; Tempalgin and Analgin, a painkiller; Tabex, drug used for smoking secession; Tribestan, drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin, used for diseases of the peripheral nervous system; Methylpredni...

• Industry: Pharmaceutical Preparations
• Founded: 1933
• Employees: 4,721
• Stock Exchange: Bulgarian Stock Exchange
• Ticker Symbol: SFA

Financial Performance

In 2023, Sopharma AD's revenue was 1.89 billion, an increase of 12.95% compared to the previous year's 1.67 billion. Earnings were 95.21 million, an increase of 33.87%.